These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 21710405)

  • 1. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
    Szulc A; Galinska B; Tarasow E; Dzienis W; Kubas B; Konarzewska B; Walecki J; Alathiaki AS; Czernikiewicz A
    Pharmacopsychiatry; 2005 Sep; 38(5):214-9. PubMed ID: 16189748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
    Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
    Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia.
    Szulc A; Konarzewska B; Galinska-Skok B; Lazarczyk J; Waszkiewicz N; Tarasow E; Milewski R; Walecki J
    Neurosci Lett; 2013 Jun; 547():37-41. PubMed ID: 23665527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are personality traits of juvenile myoclonic epilepsy related to frontal lobe dysfunctions? A proton MRS study.
    de Araújo Filho GM; Lin K; Lin J; Peruchi MM; Caboclo LO; Guaranha MS; Guilhoto LM; Carrete H; Yacubian EM
    Epilepsia; 2009 May; 50(5):1201-9. PubMed ID: 19400877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure.
    Verma A; Saraswat VA; Radha Krishna Y; Nath K; Thomas MA; Gupta RK
    Liver Int; 2008 Sep; 28(8):1095-103. PubMed ID: 18266634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of atypical antipsychotics on brain functioning in schizophrenia. A proton magnetic resonance study].
    Szulc A; Galińiska B; Tarasów E; Dzienis W; Kubas B; Konarzewska B; Waszkiewicz N; Popławska R
    Psychiatr Pol; 2010; 44(3):415-26. PubMed ID: 20672520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single voxel proton magnetic resonance spectroscopy in post-stroke depression.
    Glodzik-Sobanska L; Slowik A; McHugh P; Sobiecka B; Kozub J; Rich KE; Urbanik A; Szczudlik A
    Psychiatry Res; 2006 Dec; 148(2-3):111-20. PubMed ID: 17088051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance spectroscopy reveals an epileptic network in juvenile myoclonic epilepsy.
    Lin K; Carrete H; Lin J; Peruchi MM; de Araújo Filho GM; Guaranha MS; Guilhoto LM; Sakamoto AC; Yacubian EM
    Epilepsia; 2009 May; 50(5):1191-200. PubMed ID: 19220412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurochemical changes in welders revealed by proton magnetic resonance spectroscopy.
    Chang Y; Woo ST; Lee JJ; Song HJ; Lee HJ; Yoo DS; Kim SH; Lee H; Kwon YJ; Ahn HJ; Ahn JH; Park SJ; Weon YC; Chung IS; Jeong KS; Kim Y
    Neurotoxicology; 2009 Nov; 30(6):950-7. PubMed ID: 19631686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral diffusion tensor imaging and in vivo proton magnetic resonance spectroscopy in patients with fulminant hepatic failure.
    Saksena S; Rai V; Saraswat VA; Rathore RS; Purwar A; Kumar M; Thomas MA; Gupta RK
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e111-9. PubMed ID: 17924951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.
    Bustillo JR; Rowland LM; Jung R; Brooks WM; Qualls C; Hammond R; Hart B; Lauriello J
    Neuropsychopharmacology; 2008 Sep; 33(10):2456-66. PubMed ID: 18094668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and neuropsychological correlates of proton magnetic resonance spectroscopy detected metabolites in brains of first-episode and schizophrenic patients].
    Szulc A; Galińska B; Tarasów E; Walecki J; Dzienis W; Kubas B; Czernikiewicz A
    Psychiatr Pol; 2003; 37(6):977-88. PubMed ID: 14727370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.
    Tanaka Y; Obata T; Sassa T; Yoshitome E; Asai Y; Ikehira H; Suhara T; Okubo Y; Nishikawa T
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):365-72. PubMed ID: 16732755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of work shift on glutamic acid and gamma-aminobutyric acid (GABA): evaluation with proton magnetic resonance spectroscopy at 3T.
    Kakeda S; Korogi Y; Moriya J; Ohnari N; Sato T; Ueno S; Yanagihara N; Harada M; Matsuda T
    Psychiatry Res; 2011 Apr; 192(1):55-9. PubMed ID: 21377845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopic study.
    Brooks WM; Hodde-Vargas J; Vargas LA; Yeo RA; Ford CC; Hendren RL
    Biol Psychiatry; 1998 Feb; 43(4):263-9. PubMed ID: 9513735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia.
    Cecil KM; Lenkinski RE; Gur RE; Gur RC
    Neuropsychopharmacology; 1999 Feb; 20(2):131-40. PubMed ID: 9885793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings].
    Szulc A
    Psychiatr Pol; 2007; 41(3):329-38. PubMed ID: 17900049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.